Novo Nordisk plans to invest US$134 million (DKK 950 million) to open world-class cell facility located at Denmark, Europe.
The facility will serve as a pivotal large-scale production site, unifying a comprehensive array of expertise and services within a single location.
The facility will support various cell therapy types, encompassing those derived from embryonic stem cells, induced pluripotent stem cells, and adult stem cells.
It will offer an extensive spectrum of services ranging from process development to product GMP manufacturing, product release, and regulatory assistance.
There will be built-in flexibility that can easily switch between different types of therapies and services to keep up with the fast-changing needs of the field.
Construction of the facility is slated to commence in the summer of 2024, with the facility projected to become operational by 2027.
Name Novo Nordisk
Type New Construction
Budget US$134 million (DKK 950 million)